From The Economic Times · ET Bureau · · 1m
Cancer Drug Price Cuts Leave Costly Brands Untouched
Price cuts for cancer drugs hit generics but top brands remain unchanged.
In brief
Price cuts for cancer drugs hit generics but top brands remain unchanged. Price cuts for 137 cancer drugs cap trade margins at 30% but key patented treatments like Keytruda stay at high prices. Originally reported by The Economic Times.
Price Cuts Effective November 9
Prices of several widely used cancer drugs fall sharply from November 9 after NPPA revision.
Top Patented Drugs Unchanged
Keytruda 100 mg injections remain at ₹2,16,500, Imjudo 300 mg at ₹4,17,522, and Opdyta 100 mg at ₹1,09,450.
Generic Drugs See Steep Price Drops
Sunitinib capsules drop from ₹889 to ₹285.69, olaparib tablets from ₹15,398 to ₹2,695, and palbociclib capsules from ₹24,505 to ₹2,068.
NPPA Caps Trade Margins at 30%
NPPA revised prices for 137 cancer drugs with trade margins capped at 30% effective November 9.
Patient Assistance Programs Offer Alternative
Private hospitals may lower effective prices through patient assistance programs for patented cancer drugs.
The essence
Price cuts for 137 cancer drugs cap trade margins at 30% but key patented treatments like Keytruda stay at high prices.
